Valneva SE (NASDAQ:VALN - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $6.67, but opened at $7.40. Valneva shares last traded at $7.43, with a volume of 37,602 shares traded.
Analyst Upgrades and Downgrades
Separately, HC Wainwright dropped their price target on Valneva from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday.
View Our Latest Stock Analysis on VALN
Valneva Stock Performance
The company has a market cap of $604.57 million, a price-to-earnings ratio of -57.23 and a beta of 1.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock has a 50-day moving average price of $5.25 and a 200 day moving average price of $5.68.
Institutional Investors Weigh In On Valneva
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. AlphaCentric Advisors LLC raised its position in Valneva by 33.7% in the 3rd quarter. AlphaCentric Advisors LLC now owns 118,000 shares of the company's stock valued at $717,000 after buying an additional 29,748 shares during the last quarter. ABC Arbitrage SA acquired a new stake in Valneva in the 4th quarter valued at approximately $84,000. Finally, Wells Fargo & Company MN raised its position in Valneva by 14.3% in the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock valued at $1,079,000 after buying an additional 30,859 shares during the last quarter. Institutional investors and hedge funds own 11.39% of the company's stock.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Stories
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
